April 29, 2019 / 12:58 PM / 6 months ago

Fed Circuit sides with Eli Lilly in investor-backed challenge to drug patent

The U.S. Court of Appeals for the Federal Circuit on Friday upheld the validity of an Eli Lilly & Company patent on its cancer treatment Alimta, dealing a setback to generic drug companies seeking to market their own version of the drug.

The appeals court affirmed a determination by the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board that a patent on a vitamin regimen for Alimta users was valid.

To read the full story on Westlaw Practitioner Insights, click here: bit.ly/2XWOqrT

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below